Classical clinical trials, including the Odyssey outcomes, Fourier, Ebbinghaus and Descartes results, suggested that PCSK9 inhibitors may only lead to an increased risk of injection-site reactions, while not suggesting that PCSK9 inhibitors may cause other adverse events such as diabetes and neurocognitive dysfunction (17, 18, 57, 58). This evidence concerns the gene PCSK9 and diabetes mellitus.